At day 20 some cellulitis/superficial infection of the wound edge and BTM was evident (Figure 1B). This was managed with oral antibiotics and milking of the wound bed through small incisions of the silicone. With alternative dermal substitutes (or even a one stage reconstruction) this appearance could signal an infected site and risk failure of the matrix. In contrast, this was easily managed when using BTM by simply irrigating the area with saline and leaving it in place
- Forums
- ASX - By Stock
- PNV
- The Clinicians Speak
The Clinicians Speak, page-870
Featured News
Add PNV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$2.04 |
Change
-0.030(1.45%) |
Mkt cap ! $1.409B |
Open | High | Low | Value | Volume |
$2.09 | $2.11 | $2.03 | $1.727M | 838.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 299194 | $2.02 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.04 | 1559 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 299194 | 2.020 |
4 | 11182 | 2.010 |
9 | 86240 | 2.000 |
1 | 1500 | 1.995 |
2 | 2005 | 1.990 |
Price($) | Vol. | No. |
---|---|---|
2.040 | 1559 | 1 |
2.050 | 5436 | 2 |
2.060 | 4936 | 1 |
2.070 | 25500 | 2 |
2.100 | 10972 | 2 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
PNV (ASX) Chart |
The Watchlist
BTH
BIGTINCAN HOLDINGS LIMITED
David Keane, Co-Founder & CEO
David Keane
Co-Founder & CEO
Previous Video
Next Video
SPONSORED BY The Market Online